drugset
drugset / Trial / NCT06927232

AZA+Lus VS AZA Monotherapy in HR-MDS

NCT06927232 ↗

Phase 3 Not yet recruiting 86 enrolled Peking Union Medical College Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a randomized, prospective, single-center, open-label cohort study involving untreated HR-MDS patients. The patients were divided randomized into AZA+Lus cohort and AZA monotherapy cohort.

Timeline

Start
2025-04
Primary completion
2026-01-31
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 —
Subject Luspatercept Protein / enzyme biologic 1.75 mg/kg Subcutaneous

Indications

myelodysplastic syndrome